AN-SULFUR COLLOID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AN-SULFUR COLLOID (AN-SULFUR COLLOID).
Technetium Tc-99m sulfur colloid is a radiopharmaceutical that undergoes phagocytosis by the reticuloendothelial system (RES), primarily in the liver, spleen, and bone marrow. It allows imaging of these organs via gamma camera detection of emitted gamma rays.
| Metabolism | Primarily taken up by the RES; the colloid particles are phagocytized by Kupffer cells in the liver and macrophages in the spleen and bone marrow. No significant hepatic metabolism; biological half-life is approximately 2-3 days. |
| Excretion | Primarily via the reticuloendothelial system (liver, spleen, bone marrow) with minimal renal excretion (<2% unchanged in urine). Fecal excretion accounts for <1%. The colloid is phagocytosed by macrophages and retained in tissues; trace amounts may be excreted in bile. |
| Half-life | The terminal elimination half-life is approximately 2-5 minutes (rapid clearance from blood) for the colloid particles, followed by a slower phase of 2-3 hours for degradation of retained sulfur colloid within macrophages. Clinical context: Used for lymphoscintigraphy and liver-spleen imaging; rapid blood clearance allows imaging shortly after injection. |
| Protein binding | Minimal to negligible (<1%) for the colloid particles; however, particles are opsonized by serum proteins (e.g., complement, immunoglobulins) for phagocytosis. |
| Volume of Distribution | Approximately 0.2-0.5 L/kg, reflecting distribution primarily into blood and rapidly perfused organs (liver, spleen, bone marrow). Clinical meaning: Indicates minimal extravascular distribution; colloid is confined to the intravascular space until phagocytosed. |
| Bioavailability | Subcutaneous: Near 100% by intended route (direct interstitial injection for lymphatic uptake). Intravenous: 100% bioavailability. Oral: Not applicable (destroyed by gastric acid). |
| Onset of Action | Subcutaneous: 5-15 minutes (visualization of lymph nodes). Intravenous: Immediate (1-2 minutes for liver/spleen uptake). |
| Duration of Action | Intravenous: Imaging window of 30-60 minutes post-injection for liver/spleen; accumulation in lymph nodes may persist for 2-4 hours. Clinical notes: Duration limited by phagocytosis and redistribution; no pharmacological effect beyond imaging. |
AN-SULFUR COLLOID (technetium Tc-99m sulfur colloid) is not typically dosed in mg but as a radiopharmaceutical based on radioactivity. For liver/spleen imaging: 1-8 mCi (37-296 MBq) intravenously. For gastric emptying: 0.5-1 mCi (18.5-37 MBq) orally. For sentinel lymph node mapping: 0.4-1 mCi (14.8-37 MBq) subcutaneously or intradermally.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment required for renal impairment; Tc-99m sulfur colloid is cleared by the reticuloendothelial system, not kidneys. |
| Liver impairment | No specific dose adjustment for hepatic impairment; however, severe hepatic dysfunction may alter biodistribution and reduce liver uptake, potentially affecting image quality. Decreased hepatic clearance may prolong blood pool activity. |
| Pediatric use | Weight-based dosing: For liver/spleen imaging, administer 0.05 mCi/kg (minimum 0.5 mCi). For gastric emptying, 0.025-0.05 mCi/kg orally. For sentinel lymph node mapping, 0.1 mCi/kg subcutaneously. Use minimum doses to ensure adequate imaging counts. |
| Geriatric use | No specific dose adjustment; however, consider age-related decreases in organ function and comorbidities. Use lowest effective radioactivity to minimize radiation exposure while maintaining diagnostic image quality. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AN-SULFUR COLLOID (AN-SULFUR COLLOID).
| Breastfeeding | No data on excretion in human milk. M/P ratio unknown. Short physical half-life (6 hours) and minimal systemic absorption suggest low risk. However, caution advised. Consider pumping and discarding milk for 24 hours post-administration. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Risk to fetus is considered low due to colloidal particle size limiting placental transfer, but theoretical risk from radiation exposure exists. Use only if clearly needed and potential benefit justifies risk. Not known to be teratogenic in animal studies. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to any component of the preparation.
| Precautions | Risk of anaphylactic or hypersensitivity reactions, including rash, urticaria, and rarely anaphylaxis. Radiation exposure to patients and handlers. Use caution in patients with known hypersensitivity to human serum albumin or any component. Pregnancy and lactation: consider risks and benefits. Dose adjustment may be needed in severe hepatic impairment. |
| Food/Dietary | No known food interactions. Patients should avoid iodine-rich foods or supplements only if specifically instructed for concurrent thyroid blocking protocol (e.g., potassium perchlorate administration). |
Loading safety data…
| Fetal Monitoring | No routine monitoring required. However, consider fetal radiation dose assessment if administered during pregnancy. Monitor injection site for extravasation or allergic reactions. |
| Fertility Effects | No known effects on fertility. Not studied for reproductive impact. Theoretical risk from radiation exposure to gonads is negligible with diagnostic doses. |
| Clinical Pearls |
| AN-Sulfur Colloid (technetium Tc 99m sulfur colloid) is a radiopharmaceutical used for liver/spleen imaging, bone marrow imaging, and sentinel lymph node mapping. Key pearls: (1) Block thyroid uptake with oral potassium perchlorate (200-400 mg) 30-60 min prior to injection to minimize radiation exposure to thyroid. (2) For lymphoscintigraphy, administer intradermal or peritumoral injection; massage injection site to promote lymphatic drainage. (3) Image within 30-60 min post-injection for liver/spleen; colloid particles are cleared by reticuloendothelial system (RES) in liver, spleen, and bone marrow. (4) In severe liver disease (cirrhosis), colloid uptake shifts from liver to spleen and bone marrow (colloid shift sign). (5) Avoid extravasation; can cause local radiation injury. |
| Patient Advice | This is a radioactive tracer used to image your liver, spleen, or lymph nodes. · You will receive a small amount of radiation, similar to a diagnostic X-ray. · Drink plenty of fluids after the procedure to help eliminate the tracer from your body. · No special dietary restrictions before or after the scan. · You may feel a slight sting from the injection; massage the area if instructed for lymph node imaging. · Inform your doctor if you are pregnant or breastfeeding. · The tracer leaves your body naturally within 24 hours. |